Crhistian-Mario Oblitas

Dr. Crhistian-Mario Oblitas

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MLMarina López-Rubio
Marina López-Rubio
MRMarta Olimpia Lago Rodríguez
Marta Olimpia Lago Rodríguez
LOLucia Ordieres Ortega
Lucia Ordieres Ortega
COCrhistian-Mario Oblitas
Crhistian-Mario Oblitas
SLSergio Moragón Ledesma
Sergio Moragón Ledesma
FGFrancisco Galeano-Valle
Francisco Galeano-Valle
Catheter-related thrombosis (CRT) is a frequent and potentially serious complication associated with the widespread use of intravascular devices such as central venous catheters, including peripherally inserted central catheters and implantable port systems, pacemakers or implantable cardioverter-defibrillators. Although CRT management has been informed by guidelines extrapolated from lower extremity deep vein thrombosis (DVT), unique challenges remain due to the distinct anatomical, pathophysiological, and clinical characteristics of upper extremity DVT. Risk factors for CRT are multifactorial, encompassing patient-related characteristics such as cancer, prior venous thromboembolism, and infection, as well as catheter-specific factors like device type, lumens, and insertion site. The diagnosis of CRT relies primarily on ultrasonography; however, computed tomography angiography and magnetic resonance imaging play a complementary role, particularly in anatomically challenging cases or when complications such as pulmonary embolism or superior vena cava syndrome are suspected. Treatment strategies for CRT include anticoagulation, catheter removal when feasible, and, in select cases, local thrombolysis or catheter-directed interventions. Anticoagulation remains the cornerstone of therapy, with direct oral anticoagulants increasingly favored due to their safety profile and efficacy. This article provides a detailed review of CRT, focusing on clinical features, diagnostic methods, and treatment strategies while addressing specific challenges in managing pacemaker and hemodialysis catheter-related thrombosis.

Verified
Journal Article
Open access
PDF file
FGFrancisco Galeano-Valle
Francisco Galeano-Valle
LOLucia Ordieres Ortega
Lucia Ordieres Ortega
COCrhistian-Mario Oblitas
Crhistian-Mario Oblitas
JDJorge del-Toro-Cervera
Jorge del-Toro-Cervera
LALuis Antonio Alvarez-Sala-Walther
Luis Antonio Alvarez-Sala-Walther
Pablo Demelo‐RodríguezPablo Demelo‐Rodríguez
Pablo Demelo‐Rodríguez
The relationship between inflammation and venous thrombosis is not well understood. An inflammatory response may be both the cause and consequence of venous thromboembolism (VTE). In fact, several risk factors of VTE modulate thrombosis through inflammatory markers. Acute pulmonary embolism (PE) is burdened by a remarkable mortality rate, up to 34% in severely ill patients presenting with hemodynamic instability. Initial mortality risk stratification is based on hemodynamic instability. Patients with a situation of hemodynamic stability require immediate further risk assessment based on clinical, imaging, and circulating biomarkers, as well as the presence of comorbidities. Some inflammatory biomarkers have shown potential usefulness in the risk stratification of patients with VTE, especially acute PE. C-reactive protein on admission is associated with 30-day mortality and bleeding in VTE patients. P-selectin is associated with right ventricle dysfunction in PE patients and might be associated with VTE recurrences and the extension of thrombosis. Tissue factor microparticles are associated with VTE recurrence in cancer-associated thrombosis. Other inflammatory biomarkers present scarce evidence (inflammatory cytokines, erythrocyte sedimentation rate, fibrinogen, leukocyte count). In this manuscript, we will review the prognostic role of different inflammatory biomarkers available both for clinical practice and research in VTE patients.

6 December 2021 in Viruses
Verified
Journal Article
Open access
PDF file
COCrhistian-Mario Oblitas
Crhistian-Mario Oblitas
FGFrancisco Galeano-Valle
Francisco Galeano-Valle
JRJesús Ramírez-Navarro
Jesús Ramírez-Navarro
JLJorge López-Cano
Jorge López-Cano
ÁMÁngel Monterrubio-Manrique
Ángel Monterrubio-Manrique
Pablo Demelo‐RodríguezPablo Demelo‐Rodríguez
Pablo Demelo‐Rodríguez
Mid-regional pro-adrenomedullin (MR-proADM), methemoglobin (MetHb), and carboxyhemoglobin (COHb) levels have been associated with sepsis. In this study, we assessed the role of this potential biomarkers in critically ill COVID-19 patients. Outcomes were mortality and a combined event (mortality, venous or arterial thrombosis, and orotracheal intubation (OTI)) during a 30-day follow-up. A total of 95 consecutive patients were included, 51.6% required OTI, 12.6% patients died, 8.4% developed VTE, and 3.1% developed arterial thrombosis. MetHb and COHb levels were not associated with mortality nor combined event. Higher MR-proADM levels were found in patients with mortality (median of 1.21 [interquartile range-IQR-0.84;2.33] nmol/L vs. 0.76 [IQR 0.60;1.03] nmol/L, p = 0.011) and combined event (median of 0.91 [IQR 0.66;1.39] nmol/L vs. 0.70 [IQR 0.51;0.82] nmol/L, p < 0.001); the positive likelihood ratio (LR+) and negative likelihood ratio (LR−) for mortality were 2.40 and 0.46, respectively. The LR+ and LR− for combined event were 3.16 and 0.63, respectively. MR-proADM ≥1 nmol/L was the optimal cut-off for mortality and combined event prediction. The predictive capacity of MR-proADM showed an area under the ROC curve of 0.73 (95% CI, 0.62–0.81) and 0.72 (95% CI, 0.62–0.81) for mortality and combined event, respectively. In conclusion, elevated on-admission MR-proADM levels were associated with higher risk of 30-day mortality and 30-day poor outcomes in a cohort of critically ill patients with COVID-19.

26 February 2023 in Medicina Clinica
Verified
Journal Article
Closed access
PDPablo Demelo-Rodríguez
Pablo Demelo-Rodríguez
LOLucía Ordieres-Ortega
Lucía Ordieres-Ortega
COCrhistian-Mario Oblitas
Crhistian-Mario Oblitas

18 January 2025 in European Journal of Haematology
Verified
Journal Article
Open access
COCrhistian-Mario Oblitas
Crhistian-Mario Oblitas
MLMarta‐Olimpia Lago‐Rodríguez
Marta‐Olimpia Lago‐Rodríguez
MLMarina López-Rubio
Marina López-Rubio
MGMercedes García‐Gámiz
Mercedes García‐Gámiz
AZAngielys Zamora‐Trillo
Angielys Zamora‐Trillo
Pablo Demelo‐RodríguezPablo Demelo‐Rodríguez
Pablo Demelo‐Rodríguez
Introduction: Anticoagulant therapy is critical for venous thromboembolism (VTE) management, though bleeding remains a major concern, ranging from mild to fatal events. This study aimed to assess the predictive value of cytokines for major bleeding in patients with acute pulmonary embolism (PE).Methods: In this prospective, observational study, patients aged ≥ 18 years with acute PE were enrolled from April 2021 to September 2022 and followed for 30 days. Exclusion criteria included asymptomatic PE, VTE without PE, and chronic anticoagulation. Major bleeding was defined as bleeding that required ≥ 2 transfused units of red blood cells, occurred in critical areas, or was fatal. Blood samples were collected at diagnosis to measure IL‐6, IL‐1beta, IL‐8, IL‐10, and TNF‐alpha. Statistical analyses used bivariate and multivariate logistic regression (p < 0.05).Results: Out of 191 patients (mean age 68.6 years, 52.9% male), 8.4% died, and 4.2% experienced major bleeding within 30 days. IL‐8 > 40 pg/mL and TNF‐alpha > 8.5 pg/mL were linked to major bleeding. IL‐8 > 40 pg/mL independently predicted early major bleeding (adjusted OR 9.40; 95% CI 1.38–63.69). Cox regression showed HRs of 12.60 for IL‐8 and 5.61 for TNF‐alpha.Conclusion: High IL‐8 levels at diagnosis were predictive of major bleeding in acute PE patients. Further studies are required to confirm these findings.

22 February 2024 in Viruses
Verified
Journal Article
Open access
PDF file
COCrhistian-Mario Oblitas
Crhistian-Mario Oblitas
Pablo Demelo‐RodríguezPablo Demelo‐Rodríguez
Pablo Demelo‐Rodríguez
LALuis-Antonio Alvarez-Sala-Walther
Luis-Antonio Alvarez-Sala-Walther
MRManuel Rubio-Rivas
Manuel Rubio-Rivas
FNFrancisco Navarro-Romero
Francisco Navarro-Romero
JNJesús Millán Núñez-Cortés
Jesús Millán Núñez-Cortés
Background: This study aimed to validate the role of the D-dimer to lymphocyte ratio (DLR) for mortality prediction in a large national cohort of hospitalized coronavirus disease 2019 (COVID-19) patients. Methods: A retrospective, multicenter, observational study that included hospitalized patients due to SARS-CoV-2 infection in Spain was conducted from March 2020 to March 2022. All biomarkers and laboratory indices analyzed were measured once at admission. Results: A total of 10,575 COVID-19 patients were included in this study. The mean age of participants was 66.9 (±16) years, and 58.6% (6202 patients) of them were male. The overall mortality rate was 16.3% (n = 1726 patients). Intensive care unit admission was needed in 10.5% (n = 1106 patients), non-invasive mechanical ventilation was required in 8.8% (n = 923 patients), and orotracheal intubation was required in 7.5% (789 patients). DLR presented a c-statistic of 0.69 (95% CI, 0.68–0.71) for in-hospital mortality with an optimal cut-off above 1. Multivariate analysis showed an independent association for in-hospital mortality for DLR > 1 (adjusted OR 2.09, 95% CI 1.09–4.04; p = 0.03); in the same way, survival analysis showed a higher mortality risk for DLR > 1 (HR 2.24; 95% CI 2.03–2.47; p < 0.01). Further, no other laboratory indices showed an independent association for mortality in multivariate analysis. Conclusions: This study confirmed the usefulness of DLR as a prognostic biomarker for mortality associated with SARS-CoV-2 infection, being an accessible, cost-effective, and easy-to-use biomarker in daily clinical practice.